BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29485433)

  • 1. 18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer.
    Yamane T; Ueda S; Seto A; Kuji I
    Clin Nucl Med; 2018 May; 43(5):379-380. PubMed ID: 29485433
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
    Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
    Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
    van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [18F]FDG PET/CT for assessing inguinal lymph nodes in patients with penile cancer - correlation with histopathology after inguinal lymphadenectomy.
    Dräger DL; Heuschkel M; Protzel C; Erbersdobler A; Krause BJ; Hakenberg OW; Schwarzenböck SM
    Nuklearmedizin; 2018 Feb; 57(1):26-30. PubMed ID: 29536497
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of diagnostic sensitivity of [
    Chae SY; Son HJ; Lee DY; Shin E; Oh JS; Seo SY; Baek S; Kim JY; Na SJ; Moon DH
    EJNMMI Res; 2020 May; 10(1):54. PubMed ID: 32448947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can
    Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
    World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
    Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA
    J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic effectiveness of [
    Bottoni G; Fiz F; Puntoni M; Matteucci F; Monti M; DeCensi A; Nanni O; Brain E; Alberini JL; Dib B; Sacchetti G; Trimboli P; Treglia G; Harbeck N; Sola S; Gennari A; Piccardo A
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2477-2485. PubMed ID: 36879065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.
    Flechsig P; Kratochwil C; Schwartz LH; Rath D; Moltz J; Antoch G; Heussel CP; Rieser M; Warth A; Zabeck H; Kauczor HU; Haberkorn U; Giesel FL
    J Nucl Med; 2014 Apr; 55(4):559-64. PubMed ID: 24525209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
    Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
    Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of (18)F-2-deoxy-fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer.
    Ozawa Y; Hara M; Sakurai K; Nakagawa M; Tamaki T; Nishio M; Shibamoto Y
    Acta Radiol; 2010 Mar; 51(2):150-5. PubMed ID: 20092375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.